Artivion (AORT) Competitors $28.29 -0.53 (-1.83%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$28.28 -0.01 (-0.05%) As of 02/21/2025 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends AORT vs. NARI, NVST, PRCT, IRTC, WRBY, LIVN, ENOV, NVCR, TMDX, and LMATShould you be buying Artivion stock or one of its competitors? The main competitors of Artivion include Inari Medical (NARI), Envista (NVST), PROCEPT BioRobotics (PRCT), iRhythm Technologies (IRTC), Warby Parker (WRBY), LivaNova (LIVN), Enovis (ENOV), NovoCure (NVCR), TransMedics Group (TMDX), and LeMaitre Vascular (LMAT). These companies are all part of the "medical equipment" industry. Artivion vs. Inari Medical Envista PROCEPT BioRobotics iRhythm Technologies Warby Parker LivaNova Enovis NovoCure TransMedics Group LeMaitre Vascular Artivion (NYSE:AORT) and Inari Medical (NASDAQ:NARI) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation, dividends and community ranking. Which has more volatility & risk, AORT or NARI? Artivion has a beta of 1.75, indicating that its stock price is 75% more volatile than the S&P 500. Comparatively, Inari Medical has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500. Does the media refer more to AORT or NARI? In the previous week, Inari Medical had 8 more articles in the media than Artivion. MarketBeat recorded 8 mentions for Inari Medical and 0 mentions for Artivion. Inari Medical's average media sentiment score of 0.54 beat Artivion's score of 0.00 indicating that Inari Medical is being referred to more favorably in the news media. Company Overall Sentiment Artivion Neutral Inari Medical Positive Is AORT or NARI more profitable? Artivion has a net margin of -0.22% compared to Inari Medical's net margin of -13.68%. Artivion's return on equity of 5.15% beat Inari Medical's return on equity.Company Net Margins Return on Equity Return on Assets Artivion-0.22% 5.15% 1.91% Inari Medical -13.68%-10.09%-6.60% Does the MarketBeat Community believe in AORT or NARI? Inari Medical received 41 more outperform votes than Artivion when rated by MarketBeat users. However, 80.65% of users gave Artivion an outperform vote while only 57.89% of users gave Inari Medical an outperform vote. CompanyUnderperformOutperformArtivionOutperform Votes2580.65% Underperform Votes619.35%Inari MedicalOutperform Votes6657.89% Underperform Votes4842.11% Do insiders & institutionals believe in AORT or NARI? 86.4% of Artivion shares are held by institutional investors. Comparatively, 91.0% of Inari Medical shares are held by institutional investors. 8.1% of Artivion shares are held by company insiders. Comparatively, 10.6% of Inari Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has higher valuation & earnings, AORT or NARI? Inari Medical has higher revenue and earnings than Artivion. Artivion is trading at a lower price-to-earnings ratio than Inari Medical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArtivion$384.90M3.08-$30.69M-$0.02-1,414.70Inari Medical$574.50M8.15-$1.64M-$1.35-59.24 Do analysts prefer AORT or NARI? Artivion presently has a consensus price target of $31.80, indicating a potential upside of 12.39%. Inari Medical has a consensus price target of $68.00, indicating a potential downside of 14.97%. Given Artivion's stronger consensus rating and higher possible upside, equities analysts clearly believe Artivion is more favorable than Inari Medical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Artivion 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Inari Medical 0 Sell rating(s) 12 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.14 SummaryArtivion and Inari Medical tied by winning 9 of the 18 factors compared between the two stocks. Get Artivion News Delivered to You Automatically Sign up to receive the latest news and ratings for AORT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AORT vs. The Competition Export to ExcelMetricArtivionSurgical & medical instruments IndustryMedical SectorNYSE ExchangeMarket Cap$1.21B$4.59B$5.77B$20.07BDividend YieldN/A39.91%4.78%3.65%P/E Ratio-1,414.7031.4526.4634.90Price / Sales3.0850.78455.0215.64Price / Cash38.2151.2344.0420.85Price / Book4.126.577.634.92Net Income-$30.69M$90.13M$3.18B$1.02B7 Day Performance-5.93%-2.20%-1.91%-1.05%1 Month Performance-8.10%-2.17%-0.19%-1.09%1 Year Performance43.48%15.26%16.70%13.70% Artivion Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AORTArtivion1.4419 of 5 stars$28.29-1.8%$31.80+12.4%+44.6%$1.21B$384.90M-1,414.701,500NARIInari Medical1.6761 of 5 stars$79.93flat$68.00-14.9%+40.0%$4.68B$493.63M-59.211,300NVSTEnvista3.544 of 5 stars$21.59+0.3%$20.21-6.4%-6.5%$3.71B$2.51B-3.3312,800PRCTPROCEPT BioRobotics3.2668 of 5 stars$67.61-2.4%$97.86+44.7%+28.3%$3.53B$199.84M-34.67430Positive NewsIRTCiRhythm Technologies1.1354 of 5 stars$112.11-0.1%$108.45-3.3%+6.8%$3.51B$492.68M-23.072,000Earnings ReportAnalyst ForecastNews CoverageGap UpWRBYWarby Parker2.5425 of 5 stars$25.70-2.7%$21.77-15.3%+71.6%$2.61B$669.77M-95.193,491Upcoming EarningsAnalyst ForecastLIVNLivaNova3.5803 of 5 stars$47.68+0.1%$69.17+45.1%-16.5%$2.59B$1.15B113.522,900Upcoming EarningsENOVEnovis3.4615 of 5 stars$43.89+0.4%$64.83+47.7%-29.1%$2.50B$1.71B-20.046,550Short Interest ↓Positive NewsNVCRNovoCure3.4804 of 5 stars$22.48+3.5%$32.67+45.3%+41.4%$2.43B$509.34M-16.061,453Upcoming EarningsNews CoverageTMDXTransMedics Group3.6152 of 5 stars$72.18+1.3%$122.70+70.0%-17.3%$2.42B$241.62M76.79210News CoverageGap UpLMATLeMaitre Vascular1.9524 of 5 stars$98.65+1.7%$94.63-4.1%+59.9%$2.22B$193.48M53.91490 Related Companies and Tools Related Companies Inari Medical Competitors Envista Competitors PROCEPT BioRobotics Competitors iRhythm Technologies Competitors Warby Parker Competitors LivaNova Competitors Enovis Competitors NovoCure Competitors TransMedics Group Competitors LeMaitre Vascular Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:AORT) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artivion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artivion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
